ReviewExperimental dermatology2014
Does prostaglandin D2 hold the cure to male pattern baldness?
Review in Experimental dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 75 citations in OpenAlex.
- The efficacy of topical cetirizine using microneedling in androgenetic alopecia male patients.Archives of dermatological research · 2025Trial
- Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial.Clinical, cosmetic and investigational dermatology · 2021Trial
- Topical diclofenac gel for actinic damage in patients with alopecia.JAAD case reports · 2026Article
- Use of genetics in the prediction of success in male pattern hair loss therapy and mechanistic studies.Frontiers in pharmacology · 2026Review
- Prostaglandin FFrontiers in physiology · 2025Article
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment.Frontiers in pharmacology · 2025Review
- Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the regenerative field.Stem cell research & therapy · 2024Review
- Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment.Dermatology and therapy · 2024Article
- Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways.The British journal of dermatology · 2022Article
- Anti-inflammatory effects of the prostaglandin DVeterinary research · 2022Article
- The physiological and pharmacological roles of prostaglandins in hair growth.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2022Review
- Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review.Postepy dermatologii i alergologii · 2022Review
- Anti-Inflammatory, Thrombolytic and Hair-Growth Promoting Activity of thePlants (Basel, Switzerland) · 2021Article
- GPR44 as a Target for Imaging Pancreatic Beta-Cell Mass.Current diabetes reports · 2019Review
- Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.International journal of women's dermatology · 2018Review
- Article
- Divergent proliferation patterns of distinct human hair follicle epithelial progenitor niches in situ and their differential responsiveness to prostaglandin D2.Scientific reports · 2017Article
- Conventional and novel stem cell based therapies for androgenic alopecia.Stem cells and cloning : advances and applications · 2017Review
- Review
- 15-deoxy prostaglandin J2, the nonenzymatic metabolite of prostaglandin D2, induces apoptosis in keratinocytes of human hair follicles: a possible explanation for prostaglandin D2-mediated inhibition of hair growth.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lipids in the skin are the most diverse in the entire human body. Their bioactivity in health and disease is underexplored. Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening. An enzyme which synthesizes it, prostaglandin D2 synthase (PTGDS or lipocalin-PGDS), is hormone responsive in multiple other organs. PGD2 has two known receptors, GPR44 and PTGDR. GPR44 was found to be necessary for the decrease in hair growth by PGD2 . This creates an exciting opportunity to perhaps create novel treatments for AGA, which inhibit the activity of PTGDS, PGD2 or GPR44. This review discusses the current knowledge surrounding PGD2 , and future steps needed to translate these findings into novel therapies for patients with AGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.